Ingrida Platais


Since Gynuity was founded in 2003, we have made great strides and remain true to our vision and mission. We are proud of our achievements during more than 15 years on the frontiers of reproductive and maternal health across the globe. We share some highlights and will continue to add new achievements going forward.

Expanded use of medical abortion pills

Completed seminal clinical research demonstrating that medical abortion pills (mifepristone and misoprostol) are safe, effective and desirable to women, which ultimately paved the way for greater access to care in, for example, Bangladesh, Mexico, Tunisia, the United States, Uzbekistan and Vietnam.

Translated science into clinical policy

Conducted implementation research and translated findings into professional guidelines later adopted by FIGO, WHO and national Ministries of Health promoting new models of care, such as task sharing for first—and second-trimester medical abortion and for the management of postpartum hemorrhage

Informed drug registration processes

Provided critical clinical data for applications to regulatory agencies around the globe, enabling commercial entities to register and label medicines for reproductive and maternal health uses. For example, we provided data to support Health Canada’s registration of mifepristone and the U.S. FDA’s decision to expand outpatient medical abortion through 70 days gestational age

Conducted seminal research on misoprostol for postpartum hemorrhage

Conceived and implemented large-scale clinical and community-based research demonstrating that misoprostol, a pill that can be used to prevent blood loss at delivery and immediately after delivery, is safe and effective and a reasonable alternative to oxytocin for these purposes

Developed innovative medical abortion telemedicine service delivery model

Created the TelAbortion Project the United States’ first direct-to-patient telemedicine abortion service enabling women in some states to access medical abortion without going to an abortion clinic

Studied and promoted low-tech non-surgical postabortion care

Filled critical evidence gaps to demonstrate that misoprostol—a simple, widely available pill—can replace surgery for postabortion care (e.g. spontaneous miscarriage, incomplete abortion or postabortion complications)

Advocated for access to essential medicines

Applied for and obtained World Health Organization’s Essential Medicines List (EML) approvals for three misoprostol indications: incomplete abortion, postpartum hemorrhage prevention and postpartum hemorrhage treatment

Evaluated low-tech screening, diagnostic and treatment tools

Developed evidence to understand the role of promising low-tech screening, diagnostic and treatment tools, including at home urine multi-level pregnancy tests for medical abortion follow-up; the Congo Red Dot point-of-care test, developed to screen for pre-eclampsia; and use of uterine balloon tamponade (UBT) for managing uncontrolled PPH

Demonstrated the possibility of simplified care for hypertension in pregnancy

Generated evidence for simpler ways to treat severe hypertension in pregnancy by demonstrating a safe and effective role for oral anti-hypertensive drugs that may allow treatment in settings where IV administration and careful fetal monitoring are not possible

Validated ways to increase contraceptive access after medical abortion

Demonstrated that contraceptive injectables and implants can be “quickstarted” at the initial medical abortion visit, eliminating the need for a return visit and reducing exposure to unwanted pregnancy

Filled evidence gaps about safety of mifepristone

Generated evidence to respond to concerns about the safety of mifepristone medical abortion following a series of fatal clostridia bacterial infections, which showed that presence of clostridia bacteria is rare and transient in the vagina and rectum, and risk of infection is not increased due to medical abortion

Convened and coordinated advocacy actions to protect mifepristone in the U.S.

Established the Mifepristone Coalition bringing together more than 150 organizations and 360 individuals working in concert to increase access to mifepristone medical abortion in the U.S. We heightened awareness of the U.S. FDA’s REMS (Risk Evaluation and Mitigation Strategy) and the barriers it creates for access

Produced materials for health programs and research communities

Produced scientific and user-focused materials available in more than a dozen languages to support country programs globally, including an image bank with pictorials for trainings and research